STELLA PHARMA CORPORATION (4888) AI Stock Analysis

• Market Cap: ¥13.99B
• Dividend Yield: N/A
• Average Volume (3M): 254.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.99
• Revenue Growth: 268.05%
• EPS Growth: 83.57%
• Country: JP
• Employees: 44
• Sector: Healthcare
• Sector Strength: 50
• Industry: Biotechnology
• EPS (TTM): -4.60
• Shares Outstanding: 34,034,100
• 10 Day Avg. Volume: 156,950
• 30 Day Avg. Volume: 254,936
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥443.00
• Price Target Upside: 3.99% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 58 Neutral
• Price Target: ¥443.00 ▲(3.99% Upside)

The overall stock score is primarily influenced by strong technical momentum and solid revenue growth, despite ongoing profitability challenges. The negative P/E ratio and lack of dividend yield weigh on the valuation score, but the positive cash flow transition offers a potential path to improved financial health.

STELLA PHARMA CORPORATION Business Overview & Revenue Model

Company Description

STELLA PHARMA CORPORATION (4888) is a pharmaceutical company that specializes in the research, development, and commercialization of innovative medical treatments. Operating within the healthcare sector, the company focuses primarily on oncology, providing advanced therapeutics aimed at improving patient outcomes and quality of life. Its core products include a range of proprietary drugs and treatment solutions designed to address various forms of cancer.

How the Company Makes Money

STELLA PHARMA CORPORATION makes money through the sale of its pharmaceutical products, particularly in the oncology space. The company's revenue model primarily relies on the development and commercialization of proprietary drugs that are sold to healthcare providers, hospitals, and clinics. Revenue streams are bolstered by partnerships with other pharmaceutical companies and research institutions, which can include licensing agreements, joint ventures, and collaborative research projects. Additionally, the company may generate income from royalties on licensed technologies and products as well as government grants for research and development in therapeutic areas.

STELLA PHARMA CORPORATION Financial Statement Overview

Summary

STELLA PHARMA CORPORATION shows strong revenue growth and a solid equity base, indicating potential for future success. However, persistent operational losses and negative profit margins reveal the need for improved profitability. The transition to positive free cash flow is encouraging, suggesting better financial health if revenue growth is sustained.

Income Statement

The company has shown significant revenue growth over the years, with a remarkable increase from ¥100 million in 2022 to ¥961 million in 2025. However, the company is not profitable yet, as it continues to report negative net income and EBIT. Profit margins are negative, which is a concern as it indicates ongoing operational challenges.

Balance Sheet

The balance sheet shows a strong equity position with Stockholders' Equity consistently higher than Total Debt, resulting in a low Debt-to-Equity ratio. The equity ratio is robust, reflecting a stable financial structure. However, the presence of high net losses could affect future equity levels if not addressed.

Cash Flow

The company has improved its cash flow position, transitioning from negative free cash flow in earlier years to positive free cash flow in 2025. Operating cash flow has also turned positive, which is a positive sign for operational efficiency. However, the ratio of operating cash flow to net income is low due to significant net losses.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	961.06M	269.49M	229.07M	100.10M	205.97M
Gross Profit	811.03M	217.49M	206.94M	84.86M	181.78M
EBITDA	-99.06M	-723.85M	-738.34M	-726.86M	-621.70M
Net Income	-140.81M	-763.75M	-778.82M	-767.72M	-659.24M
Balance Sheet
Total Assets	5.42B	3.82B	4.33B	4.72B	2.05B
Cash, Cash Equivalents and Short-Term Investments	3.21B	2.35B	2.71B	3.28B	1.25B
Total Debt	766.78M	933.30M	1.09B	1.25B	1.41B
Total Liabilities	2.21B	1.44B	1.58B	1.64B	1.82B
Stockholders Equity	3.21B	2.38B	2.75B	3.08B	230.72M
Cash Flow
Free Cash Flow	136.50M	-887.82M	-857.00M	-1.13B	-795.25M
Operating Cash Flow	140.41M	-876.84M	-827.67M	-1.08B	-772.81M
Investing Cash Flow	287.58M	-9.01M	-29.93M	-350.56M	-22.86M
Financing Cash Flow	725.78M	228.35M	291.82M	3.83B	-332.40M

STELLA PHARMA CORPORATION Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 426.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4888, the sentiment is Positive. The current price of 426 is above the 20-day moving average (MA) of 415.25, above the 50-day MA of 406.50, and below the 200-day MA of 429.85, indicating a neutral trend. The MACD of 2.58 indicates Positive momentum. The RSI at 58.10 is Neutral, neither overbought nor oversold. The STOCH value of 48.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4888.

STELLA PHARMA CORPORATION Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4880	66 Neutral	¥13.20B	284.55		0.77%	-13.57%	-106.11%
4888	58 Neutral	¥13.99B	―		―	268.05%	83.57%
4579	57 Neutral	¥14.41B	―		―	40.66%	24.86%
Sector *	51 Neutral	$7.73B	-0.08	-40.59%	2.23%	22.72%	-1.44%
4583	48 Neutral	¥9.60B	―		―	30.92%	26.00%
4599	47 Neutral	¥20.01B	―		―	―	8.47%
4588	44 Neutral	¥18.78B	―		―	-9.04%	2.12%